Metagenomi Therapeutics (MGX) Net Margin (2023 - 2026)

Metagenomi Therapeutics (MGX) has reported Net Margin for 4 consecutive years, with 1847.68% the latest figure, recorded in Q1 2026.

• On a quarterly basis, Net Margin fell 124096.0% year-over-year to 1847.68% in Q1 2026; TTM through Mar 2026 was 384.61%, a 21240.0% decrease from a year earlier, with the FY2025 full-year figure at 348.54%, down 19928.0% from the prior year.
• Net Margin was 1847.68% for Q1 2026 at Metagenomi Therapeutics, down from 576.02% in the prior quarter.
• Over five years, Net Margin peaked at 53.67% in Q2 2024 and troughed at 1847.68% in Q1 2026.
• A 4-year average of 369.4% and a median of 225.36% in 2024 frame the typical range for Net Margin.
• Across the five-year window, Net Margin jumped 6107 bps in 2024 and slumped 124096 bps in 2026, its largest moves.
• Over 4 years, Net Margin stood at 155.61% in 2023, then tumbled by 56 bps to 243.37% in 2024, then sank by 137 bps to 576.02% in 2025, then slumped by 221 bps to 1847.68% in 2026.
• The last three Net Margin figures came in at 1847.68% (Q1 2026), 576.02% (Q4 2025), and 235.51% (Q3 2025), per Business Quant data.